General Gynecology
Study: Despite clinical practice guidelines recommending cervical cancer screening every 3 years or cotesting with HPV and cytologic testing every 5 years, many women get tested much more often
3 May, 2021 | 05:19h | UTC
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
M-A: Lidocaine lubricant jelly does not reduce pain perception during female urethral catheterization
27 Apr, 2021 | 09:11h | UTCLidocaine lubricant jelly does not reduce pain perception during female urethral catheterization: A systematic review with meta‐analysis and trial sequential analysis – The International Journal of Clinical Practice (link to abstract – $ for full-text)
Guideline: Prevention of Positioning Injuries During Gynecologic Surgery
25 Apr, 2021 | 20:50h | UTC
RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer
25 Apr, 2021 | 20:57h | UTC
Guideline: Diagnosis and Treatment of Endometriosis
25 Apr, 2021 | 20:46h | UTC
Guideline: Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis)
25 Apr, 2021 | 20:47h | UTC
RCT: Treatments for vulnerable older adult women with ovarian cancer compared
23 Apr, 2021 | 08:15h | UTCEfficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)
Chlamydia and gonorrhea: new recommendation to screen sexually active patients under 30
20 Apr, 2021 | 05:42h | UTCRelated USPSTF Draft Statement: Screening for Chlamydia and Gonorrhea – U.S. Preventive Services Task Force
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
30 Mar, 2021 | 03:08h | UTCNews Release: Six pregnancy complications are among red flags for heart disease later in life – American Heart Association
Covid-19: Middle aged women face greater risk of debilitating long term symptoms
28 Mar, 2021 | 22:49h | UTCCovid-19: Middle aged women face greater risk of debilitating long term symptoms – The BMJ
Linked Opinion: The stigma is real for people living with long covid – The BMJ Opinion
Special Issue: The importance of women’s health in peri‐operative care
16 Mar, 2021 | 01:42h | UTCSpecial Issue: The importance of women’s health in peri‐operative care – Anaesthesia
Cohort study: Hypertensive disorders of pregnancy linked to subsequent risk of premature mortality
10 Mar, 2021 | 08:24h | UTCHypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries: Do Hypertension Disorders of Pregnancy Increase Risk of Premature Maternal Mortality? – American College of Cardiology AND Hypertension disorders of pregnancy increase risk of premature maternal mortality – American College of Cardiology
RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer
10 Mar, 2021 | 08:18h | UTCSecondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm https://t.co/cFq41Ck9EW pic.twitter.com/5gFsIGLBDA
— The Lancet Oncology (@TheLancetOncol) March 9, 2021
WHO Report | Devastatingly pervasive: 1 in 3 women globally experience violence
10 Mar, 2021 | 08:21h | UTCDevastatingly pervasive: 1 in 3 women globally experience violence – World Health Organization
Commentary: Violence Against Women Is “Unequivocally Pervasive”, Reveals Largest WHO Study Ever – Health Policy Watch
Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk
11 Mar, 2021 | 08:35h | UTCOriginal study: Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study – Anaesthesia
Commentary on Twitter
Reported by > 100 news organisations and > 200k Twitter impressions in just a few hours!
Here is the new @CovidSurg infographic! Time to establish timing of surgery guidelines?@aneelbhangu @dnepo @JoanaffSimoes #FOAMed
🔗https://t.co/mRnV7U6u1w pic.twitter.com/BmKlxf9ZIK
— 𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 (@Anaes_Journal) March 10, 2021
Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance
5 Mar, 2021 | 08:35h | UTCRecommendations: Pharmacovigilance Evidence Review: The effect of COVID-19 vaccines on breast screening – Drug Safety Research Unit
Related: 2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
USPSTF Draft Statement: Screening for Chlamydia and Gonorrhea in Sexually Active Women
3 Mar, 2021 | 08:43h | UTCScreening for Chlamydia and Gonorrhea – U.S. Preventive Services Task Force
ACOG Committee Opinion: Health care for transgender and gender diverse individuals
3 Mar, 2021 | 08:41h | UTCHealth Care for Transgender and Gender Diverse Individuals – Obstetrics & Gynecology
RCT: Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years
26 Feb, 2021 | 08:34h | UTCCommentaries: The story of the Mumbai breast screening study – The BMJ Opinion
This trial found that regular breast examination by trained female health workers in Mumbai led to earlier diagnosis and reduced deaths from breast cancer in women aged 50 and olderhttps://t.co/TQCHLbVO8L
— The BMJ (@bmj_latest) February 25, 2021
RCT: Treatment of uterine fibroid symptoms with Relugolix combination therapy
19 Feb, 2021 | 02:08h | UTC
RCT: Levonorgestrel-releasing intrauterine system vs. endometrial ablation for heavy menstrual bleeding
18 Feb, 2021 | 02:38h | UTC
Cost-effective analysis suggests incorporating baseline breast density at 40 years to determine the frequency of screening in women at average risk for breast cancer
10 Feb, 2021 | 01:37h | UTCIncorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer: A Cost-Effectiveness Analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries: Screening based on breast density at age 40 may reduce breast cancer mortality – ACP Internist AND Screening strategy based on baseline breast density at age 40 may be effective for reducing breast cancer mortality – American College of Physicians AND For Mammography: Baseline at 40 Makes Sense – Diagnostic Imaging
Commentary on Twitter
New research led by @TinaShihHSR of @MDAndersonNews found screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing #breastcancer mortality https://t.co/9f0P7CSCmD. pic.twitter.com/PemE8XVSqr
— Annals of Int Med (@AnnalsofIM) February 9, 2021
Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions
10 Feb, 2021 | 01:25h | UTC
Commentary on Twitter
Cardiovascular health during menopause, pregnancy, and other gynaecologic conditions: European multidisciplinary consensus is out !https://t.co/fm6EBEbhVO.#cardiotwitter, @ESC_Journals, @escardio, #gynecology pic.twitter.com/WIekM50b07
— EHJ Editor-in-Chief (@ehj_ed) January 26, 2021
Randomized trial: Levonorgestrel vs. copper intrauterine devices for emergency contraception
28 Jan, 2021 | 01:27h | UTCVisual abstract: Levonorgestrel vs. Copper IUDs for Emergency Contraception